FDA / ICH reference questions

**Fast regulation search** Searched the local FDA/ICH regulation database and found **6 matching sources** for: _What is risk-based monitoring according to FDA guidance?_ --- ## Source 1: FDA Guidance — Risk-Based Monitoring Overview **Reference:** `FDA Guidance: Risk-Based Monitoring (2019)` **Category:** Monitoring **Match Score:** 1.2786 The FDA Guidance on Risk-Based Monitoring (published 2013, updated 2019) recommends that sponsors shift from routine 100% source data verification (SDV) to a risk-based approach. Key concepts include: (1) Focus monitoring on critical data and processes that protect human subjects and ensure data integrity. (2) Use centralized monitoring to complement on-site visits. (3) Identify critical-to-quality factors. (4) Use analytics to detect data anomalies, unusual patterns, and trends across trial sites. (5) The extent of on-site monitoring should be justified based on risk assessment. (6) The monitoring plan should be tailored to the specific risks of each trial. --- ## Q&A 2: What is Risk-Based Monitoring (RBM)? **Category:** Monitoring **Source:** `ICH GCP 5.18.3` **Answer:** Monitoring approach per ICH GCP 5.18.3 that focuses on critical data and processes instead of 100% SDV. Uses centralized monitoring, statistical analysis, and targeted on-site visits. --- ## Q&A 3: What is ICH GCP E6(R2)? **Category:** GCP Basics **Source:** `ICH E6(R2) Guideline` **Answer:** ICH GCP E6(R2) is the International Council for Harmonisation guideline for Good Clinical Practice. R2 (2016 addendum) emphasizes Risk-Based Monitoring, source data verification, and quality management in clinical trials. --- ## Source 4: CRA Practice — Monitoring Visit Preparation and Conduct **Reference:** `ICH GCP E6(R2) Section 5.18 + FDA Guidance on Risk-Based Monitoring` **Category:** Monitoring **Match Score:** 0.4881 PRACTICAL MONITORING VISIT GUIDE per ICH GCP 5.18: BEFORE THE VISIT (preparation): 1. Review previous monitoring visit report and follow-up items 2. Check open queries and query aging report 3. Review subject enrollment and status report 4. Check for protocol deviations since last visit 5. Review SAEs and AEs reported since last visit 6. Confirm date/time with site coordinator 7. Prepare monitoring visit plan / focus areas 8. Review essential documents binder (regulatory) AT THE VISIT (conduct): 1. Opening meeting with PI and coordinator — confirm visit scope 2. SDV per monitoring plan (subjects, data points, %) 3. Review regulatory documents (IRB, ICFs, 1572) 4. Check drug accountability and temperature logs 5. Review AEs/SAEs and follow-up status 6. Address open items from previous visit 7. Document all findings in monitoring visit report 8. Conduct close-out meeting with PI — discuss findings 9. Request documents for follow-up (if applicable) AFTER THE VISIT: 1. Finalize and submit monitoring visit report within 5 business days 2. Issue queries for discrepancies found 3. Follow up on unresolved items 4. Update site tracking systems RISK-BASED MONITORING (ICH GCP 5.18.3): - Central monitoring: review data trends, query rates, enrollment patterns - On-site monitoring: targeted SDV based on risk indicators - Adjust monitoring frequency based on site performance and risk --- ## Q&A 5: What are Critical-to-Quality (CtQ) factors? **Category:** Monitoring **Source:** `FDA Guidance RBM 2019` **Answer:** Essential attributes for: (a) subject protection, (b) reliable results, (c) credible decisions. Sponsors should identify CtQ factors and focus monitoring accordingly. Per FDA Guidance. --- ## Q&A 6: What is Centralized Monitoring? **Category:** Monitoring **Source:** `ICH E6(R2) Addendum` **Answer:** Remote evaluation of accumulating data using statistics and visualization. Identifies: missing data, inconsistencies, outliers, fraud, and protocol deviation patterns. Per ICH E6(R2) Addendum. --- *Tip: Try rephrasing your question for more targeted matches.*